Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.

Find Full text
Thumbnail
Fulltext:
307681.pdf
Embargo:
until further notice
Size:
956.9Kb
Format:
PDF
Description:
Publisher’s version
Publication year
2024
Author(s)
Thomas, S. E.
Seyger, M.M.B.
Mangnus, J.E.
Otero, M.E.
Gostynski, A.H.
Njoo, M.D.
Ossenkoppele, P.M.
Haeck, I.M.
Hendricksen-Roelofzen, J.H.J.
Körver, J.E.M.
Dodemont, S.R.P.
Tupker, R.A.
Berends, Matthijs S.
Weppner-Parren, L.M.J.T.
Keijsers, R.R.M.C.
Oostveen, A.M.
Peters, B.
Mommers, R.
Doorn, M.B.A. van
Tjioe, M.
Veldkamp, W.R.
Kuijpers, A.L.A.
Kleinpenning, M.M.
Jong, E.M.G.J. de
Reek, J.M.P.A. van den
Source
American Journal of Clinical Dermatology, 25, 4, (2024), pp. 685-688
ISSN
DOI
Annotation
01 juli 2024
Publication type
Article / Letter to editor
Please use this identifier to cite or link to this item: https://hdl.handle.net/2066/307681   https://hdl.handle.net/2066/307681
Display more details

Upload full text

Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.